MaltSci 麦伴科研

Appearance

Popular Reports / Clinical Medicine

This report is written by MaltSci based on the latest literature and research findings

How are respiratory diseases diagnosed? ​

Abstract ​

Respiratory diseases represent a significant global health challenge, affecting millions of individuals and imposing substantial economic burdens on healthcare systems. Conditions such as asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and lung cancer are among the most prevalent respiratory disorders, each characterized by a unique set of symptoms and pathophysiological mechanisms. Accurate diagnosis of these diseases is critical, as it informs treatment decisions and plays a vital role in improving patient outcomes and reducing healthcare costs. Recent advancements in medical technology and diagnostic methodologies have transformed the landscape of respiratory disease diagnosis, enabling earlier and more precise identification of these conditions. This review systematically explores various diagnostic approaches, including clinical evaluation methods, imaging techniques, pulmonary function tests, and laboratory analyses. Clinical evaluation remains the cornerstone of diagnosis, relying on thorough patient history and symptom assessment. Imaging techniques, such as chest X-rays and CT scans, provide critical visual insights into lung pathology, while pulmonary function tests assess the functional capacity of the respiratory system. Laboratory analyses, including blood tests and sputum examinations, further complement the diagnostic process by identifying specific pathogens or biomarkers associated with respiratory diseases. Despite these advancements, challenges persist in the diagnostic process, including misdiagnosis and accessibility issues, particularly in low-resource settings. Future directions in diagnostic approaches focus on the potential of advances in biomarkers and the role of artificial intelligence and machine learning in enhancing diagnostic accuracy. By providing a comprehensive overview of the diagnostic landscape for respiratory diseases, this report aims to serve as a valuable resource for healthcare professionals, researchers, and policymakers dedicated to improving respiratory health.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Clinical Evaluation of Respiratory Diseases
    • 2.1 Patient History and Symptoms
    • 2.2 Physical Examination Techniques
  • 3 Imaging Techniques in Diagnosis
    • 3.1 Chest X-ray
    • 3.2 Computed Tomography (CT) Scans
    • 3.3 Magnetic Resonance Imaging (MRI)
  • 4 Pulmonary Function Tests
    • 4.1 Spirometry
    • 4.2 Diffusion Capacity Testing
    • 4.3 Peak Flow Measurement
  • 5 Laboratory Analyses
    • 5.1 Blood Tests
    • 5.2 Sputum Analysis
    • 5.3 Bronchoscopy and Biopsy
  • 6 Challenges and Limitations in Diagnosis
    • 6.1 Misdiagnosis and Overlapping Symptoms
    • 6.2 Accessibility and Resource Limitations
  • 7 Future Directions in Diagnostic Approaches
    • 7.1 Advances in Biomarkers
    • 7.2 Role of Artificial Intelligence and Machine Learning
  • 8 Summary

1 Introduction ​

Respiratory diseases represent a significant global health challenge, affecting millions of individuals and imposing substantial economic burdens on healthcare systems. Conditions such as asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and lung cancer are among the most prevalent respiratory disorders, each characterized by a unique set of symptoms and pathophysiological mechanisms. Accurate diagnosis of these diseases is critical, as it not only informs treatment decisions but also plays a vital role in improving patient outcomes and reducing healthcare costs [1]. Recent advancements in medical technology and diagnostic methodologies have transformed the landscape of respiratory disease diagnosis, enabling earlier and more precise identification of these conditions [2].

The significance of effective diagnostic strategies cannot be overstated. Timely and accurate diagnosis can lead to better management of respiratory diseases, ultimately enhancing patients' quality of life and reducing the risk of severe complications [1]. Furthermore, with the rise of antibiotic resistance and the emergence of new respiratory pathogens, the need for robust diagnostic frameworks has become increasingly urgent [3]. In this context, healthcare professionals, researchers, and policymakers are actively seeking innovative approaches to enhance the accuracy and efficiency of respiratory disease diagnosis [4].

Currently, the diagnostic landscape for respiratory diseases is diverse, encompassing a range of traditional and novel methodologies. Clinical evaluation remains the cornerstone of diagnosis, relying on thorough patient history, symptom assessment, and physical examination techniques [2]. Imaging techniques, such as chest X-rays and computed tomography (CT) scans, provide critical visual insights into lung pathology, while pulmonary function tests assess the functional capacity of the respiratory system [5]. Laboratory analyses, including blood tests and sputum examinations, further complement the diagnostic process by identifying specific pathogens or biomarkers associated with respiratory diseases [2][6].

Despite these advancements, challenges persist in the diagnostic process. Misdiagnosis and overlapping symptoms can lead to inappropriate treatment and poor patient outcomes [7]. Accessibility and resource limitations further complicate the situation, particularly in low-resource settings where advanced diagnostic tools may not be readily available [1]. Thus, addressing these challenges is paramount for improving diagnostic accuracy and ensuring equitable access to healthcare.

This review will systematically explore the various diagnostic approaches employed in the assessment of respiratory diseases, organized as follows: first, we will delve into clinical evaluation methods, highlighting the importance of patient history and physical examination techniques. Next, we will examine imaging techniques, including chest X-rays, CT scans, and magnetic resonance imaging (MRI), and their roles in diagnosis. The discussion will then transition to pulmonary function tests, emphasizing spirometry, diffusion capacity testing, and peak flow measurement. Following this, we will analyze laboratory analyses, focusing on blood tests, sputum analysis, and bronchoscopy with biopsy.

Subsequently, we will address the challenges and limitations faced in the diagnostic process, including issues of misdiagnosis and resource constraints. Finally, we will explore future directions in diagnostic approaches, particularly the potential of advances in biomarkers and the role of artificial intelligence and machine learning in enhancing diagnostic accuracy. By providing a comprehensive overview of the diagnostic landscape for respiratory diseases, this report aims to serve as a valuable resource for healthcare professionals, researchers, and policymakers dedicated to improving respiratory health.

2 Clinical Evaluation of Respiratory Diseases ​

2.1 Patient History and Symptoms ​

Respiratory diseases are commonly diagnosed through a multifaceted approach that includes clinical evaluation, patient history, and symptom assessment. A thorough understanding of the patient's history is critical in identifying respiratory conditions, as many respiratory diseases present with overlapping symptoms.

In clinical practice, the initial evaluation typically begins with a detailed patient history, which encompasses inquiries about the duration and nature of symptoms, previous respiratory illnesses, and exposure to risk factors such as smoking, environmental pollutants, or infectious agents. This information aids clinicians in forming a differential diagnosis. For instance, asthma and chronic obstructive pulmonary disease (COPD) are prevalent chronic respiratory diseases characterized by distinct symptom profiles, such as wheezing, dyspnea, and chronic cough, which can guide further diagnostic testing [8].

Symptoms reported by patients, including the presence of cough, sputum production, and breathlessness, are critical in evaluating respiratory health. The specific characteristics of these symptoms, such as their onset, frequency, and any associated factors, can provide insights into the underlying pathology. For example, acute respiratory infections may present with sudden onset of symptoms, whereas chronic conditions might have a more gradual progression [5].

Diagnostic testing complements clinical evaluation and is essential for confirming the diagnosis. Techniques vary widely and can include non-invasive methods such as exhaled breath condensate (EBC) analysis, which offers valuable biomarkers indicative of inflammatory and neoplastic states in the lungs [8]. Moreover, the advent of molecular diagnostic methods, including polymerase chain reaction (PCR) and other amplification techniques, has significantly enhanced the speed and accuracy of diagnosing infectious respiratory diseases [9].

In children, laboratory diagnostics have evolved to include rapid assays that are highly sensitive and specific, thus allowing for timely identification of pathogens responsible for respiratory infections [5]. This is crucial as early identification can lead to appropriate antimicrobial therapy and improved patient outcomes.

Overall, the diagnosis of respiratory diseases is a complex process that requires careful consideration of clinical symptoms, patient history, and the application of various diagnostic techniques to achieve accurate results. The integration of emerging technologies, such as artificial intelligence in diagnostic frameworks, is also paving the way for more precise and personalized approaches to respiratory disease management [4].

2.2 Physical Examination Techniques ​

The diagnosis of respiratory diseases involves a multifaceted approach that encompasses clinical evaluation, physical examination techniques, and various diagnostic tools. Physical examination plays a crucial role in the initial assessment of patients presenting with respiratory symptoms. Key components of this examination include inspection, palpation, percussion, and auscultation.

During the inspection phase, healthcare providers observe the patient for any signs of respiratory distress, such as labored breathing, use of accessory muscles, and cyanosis. The posture of the patient can also provide insights; for instance, patients with severe respiratory distress may adopt a tripod position to facilitate breathing.

Palpation involves the assessment of thoracic expansion and tactile fremitus. By placing hands on the patient's chest while they take deep breaths, clinicians can evaluate symmetrical expansion of the lungs. An increased tactile fremitus, where vibrations are felt more prominently, may indicate consolidation in the lungs, as seen in pneumonia.

Percussion is utilized to assess the underlying lung structures. The clinician taps on the chest wall to determine the presence of fluid, air, or solid masses within the thoracic cavity. Dullness on percussion may suggest pleural effusion or consolidation, while hyper-resonance may indicate conditions such as pneumothorax.

Auscultation is perhaps the most critical aspect of the physical examination in diagnosing respiratory diseases. Using a stethoscope, clinicians listen for normal breath sounds as well as abnormal sounds such as wheezes, crackles, or rhonchi. These abnormal sounds can provide valuable information about the underlying pathology. For example, wheezing may indicate bronchoconstriction, while crackles can suggest fluid in the alveoli.

In addition to these physical examination techniques, the diagnostic process may involve laboratory tests and imaging studies. Advanced laboratory methods, such as polymerase chain reaction (PCR) tests, have significantly improved the rapid and accurate diagnosis of respiratory infections, particularly in pediatric populations where early identification is crucial for effective management (Das et al. 2018). Moreover, the evolution of multiplex PCR assays has enhanced the ability to identify multiple pathogens simultaneously, thus facilitating timely treatment decisions (Diaz-Decaro et al. 2018).

Emerging technologies, including machine learning algorithms and AI-driven frameworks, are also being explored to enhance diagnostic accuracy and efficiency in respiratory disease classification (Gürkan Kuntalp et al. 2024). These systems can analyze complex data from various sources, including respiratory sounds, to assist clinicians in making more informed decisions.

In summary, the diagnosis of respiratory diseases is a comprehensive process that integrates clinical evaluation through physical examination techniques with advanced diagnostic tools. The combination of these approaches allows for accurate identification of respiratory conditions, ultimately guiding effective treatment strategies.

3 Imaging Techniques in Diagnosis ​

3.1 Chest X-ray ​

Chest X-ray (CXR) is a pivotal imaging technique utilized in the diagnosis of respiratory diseases. It serves as a non-invasive and readily accessible tool for initial assessment and evaluation of various pulmonary conditions. The diagnostic utility of CXR is particularly pronounced in the context of pneumonia, chronic obstructive pulmonary disease (COPD), lung cancer, and other thoracic abnormalities.

CXR provides a general orientation as an initial diagnostic study, particularly effective in identifying pneumonia, cancer, and COPD. Its advantages include the relatively low radiation dose involved, which ranges from 0.1 to 0.2 mSv for a single view, making it a safer option for patients compared to other imaging modalities such as computed tomography (CT) [10]. The positive predictive value (PPV) of CXR in diagnosing pneumonia, however, is limited; studies indicate a PPV of only 27% when compared to CT as the gold standard [10].

Recent advancements in imaging technology have significantly enhanced the role of CXR in clinical practice. The integration of artificial intelligence (AI) into chest radiography has shown promise in improving diagnostic accuracy and efficiency. For instance, automated systems based on deep learning algorithms have been developed to classify chest X-ray images rapidly and accurately, achieving area under the curve values of 98% and 97% for various chest diseases [11]. This AI-driven approach aids radiologists by expediting the identification of lung diseases, thus facilitating timely interventions [11].

Moreover, the evolution of CXR techniques, including the development of digital imaging, has enabled computer-aided diagnosis (CAD) systems to become more prevalent in clinical settings. These systems utilize image preprocessing methods such as contrast enhancement and segmentation to improve the visibility of lung pathologies [12]. The automated detection of specific diseases like pulmonary nodules and tuberculosis has been a focal point of research, indicating a shift towards more efficient diagnostic processes [12].

While CXR remains a cornerstone in the diagnosis of respiratory diseases, it is essential to recognize its limitations. The accuracy of CXR can be influenced by various factors, including the quality of the image, the experience of the radiologist, and the specific lung condition being assessed. As such, it is often complemented by other imaging modalities such as CT and MRI, which provide more detailed anatomical information and functional insights [13].

In conclusion, chest X-ray is a fundamental imaging technique in the diagnosis of respiratory diseases, offering a balance of accessibility, safety, and effectiveness. The integration of advanced technologies, including AI and CAD systems, continues to enhance its diagnostic capabilities, paving the way for improved patient outcomes in respiratory healthcare. However, it is critical to consider the context of its use and the potential need for supplementary imaging modalities to ensure comprehensive evaluation and management of lung diseases.

3.2 Computed Tomography (CT) Scans ​

The diagnosis of respiratory diseases has significantly evolved with the advancement of imaging techniques, particularly computed tomography (CT) scans. CT scans are considered the modality of choice for imaging thoracic and lung structures due to their ability to provide detailed anatomical information and functional insights into various pulmonary conditions.

In the context of chronic obstructive pulmonary disease (COPD), CT imaging is instrumental in identifying key morphological features such as emphysema, bronchial wall thickening, and gas trapping. While its role in the routine investigation and management of COPD is still being defined, lung CT is already pivotal in diagnosing concomitant pathologies and determining patient eligibility for interventions like lung volume reduction procedures. Moreover, novel quantitative analysis techniques derived from CT imaging facilitate objective measurements of both pulmonary and extrapulmonary manifestations of the disease, offering valuable insights into the heterogeneity and underlying mechanisms of COPD. These advancements hold promise for enhancing clinical trials aimed at developing disease-specific therapies and optimizing treatment outcomes for patients [14].

CT scans also play a crucial role in assessing small airway diseases, including asthma and COPD. High-resolution computed tomography (HRCT) is particularly effective in studying diffuse diseases and small airway involvement. The protocol for evaluating small airway diseases often includes expiratory high-resolution CT scans, which can reveal direct morphological signs of bronchiolar involvement or indirect signs such as air trapping and mosaic patterns. In asthmatic patients, multi-detector CT (MDCT) correlates clinical symptoms with airway wall thickening and airflow obstruction, thereby aiding in the quantitative evaluation of conditions like emphysema [15].

Furthermore, the application of CT imaging extends to the management of chest infections. Conventional CT has been shown to be effective in diagnosing pulmonary diseases, while advancements such as HRCT and spiral CT have improved the detection and characterization of parenchymal lung infections and their complications. For immunocompetent patients, CT findings assist in disease staging, differentiating infections from tumors, and identifying complications. In immunocompromised patients, HRCT is particularly useful for early detection of subtle infiltrates [16].

The utility of CT imaging in acute respiratory distress syndrome (ARDS) is also noteworthy. Increasingly utilized in ARDS patients, CT scans have provided insights into the pathophysiology of the condition and mechanical ventilation strategies. Newer fast CT scan technologies offer dynamic views of lung ventilation, enhancing the understanding of recruitment-derecruitment phenomena associated with ARDS [17].

Overall, CT scans are indispensable in the diagnostic landscape of respiratory diseases, offering high-resolution imaging that facilitates early detection, precise characterization, and informed management of various pulmonary conditions. As imaging technology continues to advance, the role of CT in respiratory diagnostics is expected to expand further, potentially incorporating automated segmentation techniques for enhanced analysis of pulmonary structures [18].

3.3 Magnetic Resonance Imaging (MRI) ​

Magnetic Resonance Imaging (MRI) has emerged as a pivotal tool in the diagnosis and evaluation of respiratory diseases, particularly due to its ability to provide functional and structural insights without the use of ionizing radiation. The application of MRI in this field has significantly expanded over the years, owing to technological advancements and the development of novel imaging techniques.

Historically, the assessment of lung diseases primarily relied on computed tomography (CT) and chest radiography, which, while effective for structural imaging, lacked functional information and exposed patients to significant radiation. In contrast, MRI offers a non-invasive alternative that can capture both anatomical and physiological aspects of lung function. Notably, hyperpolarized gas MRI, utilizing gases such as helium-3 and xenon-129, has gained prominence for its ability to visualize ventilation and gas exchange at a microstructural level [19].

Recent literature highlights the advantages of MRI in assessing regional lung function, which is crucial for diagnosing various pulmonary conditions that often present with heterogeneous involvement. For instance, dynamic imaging capabilities allow for the evaluation of diaphragmatic and chest wall motion, as well as static and dynamic lung volumes [20]. This is particularly beneficial in the context of chronic lung diseases such as asthma and cystic fibrosis, where traditional diagnostic methods may fall short [21].

Emerging MRI techniques, including fluorinated gas MRI and oxygen-enhanced MRI, are also being explored for their potential to interrogate lung function more effectively. These methods are currently at various stages of development, indicating a robust future for MRI in respiratory diagnostics [21].

Furthermore, the lack of ionizing radiation makes MRI particularly suitable for pediatric populations, where the need for repeated imaging is common due to the chronic nature of many respiratory diseases [22]. The review by Kirby et al. emphasizes that MRI can facilitate intensive serial and longitudinal studies in pediatric patients, addressing unmet therapeutic needs in this demographic [19].

Overall, the integration of MRI into the diagnostic workflow for respiratory diseases not only enhances the understanding of lung physiology but also improves the specificity and sensitivity of detecting ventilation defects compared to traditional methods [23]. As research continues to evolve, MRI is poised to play an increasingly vital role in the clinical management of respiratory diseases, contributing to better patient outcomes through more accurate diagnostics and tailored therapeutic strategies.

4 Pulmonary Function Tests ​

4.1 Spirometry ​

Respiratory diseases are primarily diagnosed through pulmonary function tests (PFTs), with spirometry being the most commonly utilized method. Spirometry serves as an essential tool in evaluating and monitoring respiratory conditions, and its utility extends beyond respiratory medicine into primary care and other fields. The evaluation of respiratory diseases often relies on the assessment of lung function, with spirometry remaining central due to its prognostic significance and ability to define the severity of airway diseases (King 2011; García-Río et al. 2013).

Spirometry measures various lung function parameters, primarily focusing on airflow and volume. The test typically involves a patient taking a deep breath and forcefully exhaling into a spirometer, which records the volume of air exhaled over time. Key spirometric parameters include forced vital capacity (FVC) and forced expiratory volume in one second (FEV1), which are critical for diagnosing obstructive airway disorders such as asthma and chronic obstructive pulmonary disease (COPD). These parameters allow clinicians to assess the degree of airway obstruction and determine the severity of the disease (Liou and Kanner 2009).

The accuracy and reliability of spirometry depend on several factors, including proper technique, the quality of the spirometer, and adherence to established performance standards. Guidelines emphasize the importance of using calibrated equipment, ensuring proper patient instruction, and adhering to criteria for acceptability and repeatability of measurements (Evans and Scanlon 2003). Additionally, reference equations tailored to the demographic characteristics of the patient population are vital for interpreting spirometric results accurately.

Emerging technologies are enhancing the diagnostic capabilities of spirometry. Newer methods, such as the forced oscillation technique and multiple breath nitrogen washout, are being integrated into clinical practice to provide further insights into lung function and disease pathophysiology (King 2011). These advancements may improve the diagnostic accuracy for conditions that traditional spirometry may not fully elucidate.

In conclusion, the diagnosis of respiratory diseases is fundamentally anchored in pulmonary function testing, particularly spirometry. The test's ability to provide quantitative measures of lung function makes it indispensable for the assessment, diagnosis, and management of various respiratory disorders, thereby guiding therapeutic interventions and improving patient outcomes (Sylvester et al. 2025).

4.2 Diffusion Capacity Testing ​

The diagnosis of respiratory diseases often involves a variety of pulmonary function tests (PFTs), among which diffusion capacity testing plays a crucial role. Diffusion capacity testing specifically assesses the ability of the lungs to transfer gas from the alveoli to the blood, which is a vital aspect of pulmonary function.

Diffusion capacity testing is typically performed using a method known as the single-breath carbon monoxide diffusion test (DLCO). In this test, a patient inhales a small amount of carbon monoxide (CO) along with a tracer gas (often helium), and then exhales. The concentration of CO in the exhaled air is measured to determine how effectively gas is exchanged in the lungs. This test is particularly useful for diagnosing conditions that affect the alveolar-capillary membrane, such as interstitial lung disease, pulmonary fibrosis, and emphysema.

The significance of diffusion capacity testing lies in its ability to detect early pulmonary disease, even before symptoms manifest. For instance, certain tests such as the alveolar-arterial gradient can provide insights into early pulmonary issues, allowing for timely intervention. It is essential to interpret the results of diffusion capacity testing in conjunction with other pulmonary function tests, such as spirometry, which measures airflow and can indicate obstructive or restrictive lung diseases. The combination of these tests provides a comprehensive evaluation of lung function and helps clinicians understand the underlying pathophysiology in patients with respiratory conditions [24].

Furthermore, the role of diffusion capacity testing extends beyond diagnosis; it is also instrumental in preoperative assessments and monitoring disease progression or response to treatment. For example, in the context of surgical planning, if both spirometry and diffusion capacity tests are normal, it suggests that there are no pulmonary contraindications for the planned surgery. Conversely, significant compromise in these tests may necessitate further evaluation of regional lung function to guide surgical decisions [25].

In conclusion, diffusion capacity testing is a critical component of pulmonary function testing that aids in the diagnosis and management of various respiratory diseases. Its ability to reveal gas exchange abnormalities makes it an invaluable tool in clinical practice, complementing other tests to provide a detailed understanding of a patient's respiratory health [26][27].

4.3 Peak Flow Measurement ​

Respiratory diseases are diagnosed through a combination of clinical assessments and pulmonary function tests (PFTs), which play a crucial role in evaluating lung function and identifying various respiratory conditions. Among these tests, peak flow measurement (PFM) is a significant method used to assess airflow obstruction, particularly in conditions such as asthma and chronic obstructive pulmonary disease (COPD).

Peak flow measurement involves the use of a peak flow meter, which quantifies the maximum speed of expiration, known as peak expiratory flow rate (PEFR). This measurement is valuable for monitoring respiratory function over time, especially in patients with asthma. Serial monitoring of PEFR can yield high diagnostic sensitivity and specificity for occupational asthma, making it a preferred first-line investigation for workers suspected of having this condition (Anees 2003). It is essential that PEFR records are accurately kept, plotted, and analyzed to provide reliable diagnostic insights.

The importance of PFM lies in its ability to detect changes in airway obstruction that may not be apparent through clinical history alone. In a study involving various patients with restrictive pulmonary disorders, it was found that peak expiratory flow correlated well with forced vital capacity, indicating its utility beyond just diagnosing airflow obstruction (Morris & Taylor 1990). Furthermore, home monitoring of PEFR has been shown to facilitate early recognition and treatment of asthma exacerbations, leading to improved management outcomes such as reduced symptoms and fewer hospitalizations (Li 1995).

In addition to peak flow measurement, other pulmonary function tests, such as spirometry, body plethysmography, and diffusing capacity, are routinely used to assess lung function. Spirometry remains the cornerstone of lung function assessment, providing essential information regarding the severity of airway diseases (King 2011). Emerging techniques, including forced oscillation technique and multiple breath nitrogen washout, are also gaining traction as they offer refined measurements of pulmonary mechanics and disease characterization (Zimmermann et al. 2019).

Overall, the diagnosis of respiratory diseases is enhanced by the application of these objective methods, particularly when they are employed in a stepwise manner to improve diagnostic accuracy. By integrating various tests, healthcare providers can achieve a more comprehensive understanding of a patient's respiratory health, allowing for better-targeted treatments and improved patient outcomes (Post et al. 1998).

5 Laboratory Analyses ​

5.1 Blood Tests ​

Respiratory diseases are diagnosed through various laboratory analyses, with blood tests playing a significant role, particularly in the context of arterial blood gas (ABG) analysis. Blood gas analysis serves as a diagnostic tool to evaluate the partial pressures of gases in blood and assess acid-base content. This method provides a clear understanding of respiratory, circulatory, and metabolic disorders, crucial for diagnosing conditions such as chronic respiratory failure, severe sepsis, and diabetic ketoacidosis.

The arterial blood gas analysis specifically examines blood taken from an artery, allowing for the assessment of the patient's partial pressure of oxygen (PaO2) and carbon dioxide (PaCO2), as well as pH levels. The PaO2 measurement indicates the oxygenation status of the patient, while PaCO2 reflects the ventilation status, which can indicate either chronic or acute respiratory failure. These measurements can be influenced by various factors; for instance, hyperventilation is characterized by rapid or deep breathing, while hypoventilation is characterized by slow or shallow breathing.

Additionally, the acid-base balance is evaluated through the ABG procedure, which directly measures pH and PaCO2. The use of the Henderson-Hasselbalch equation further allows for the calculation of serum bicarbonate (HCO3) and the base deficit or excess. The measured HCO3 is derived from a strong alkali that releases all CO2 in serum, including dissolved CO2 and carbamino compounds. The total CO2 calculated through standard chemistry analysis provides critical insights into the patient's metabolic state, typically yielding a difference of around 1.2 mmol/L.

Although ABG analysis is frequently utilized in emergency medicine for acute conditions, its application extends to other clinical settings, demonstrating its utility in diagnosing a wide array of diseases known as acid-base diseases (ABDs). These include severe sepsis, septic shock, hypovolemic shock, chronic heart failure, and various metabolic disorders, highlighting the comprehensive diagnostic capabilities of blood gas analysis in respiratory medicine [28].

In summary, blood tests, particularly arterial blood gas analysis, are essential in diagnosing respiratory diseases, providing vital information regarding gas exchange, acid-base balance, and overall respiratory function, thereby guiding effective clinical management and treatment strategies.

5.2 Sputum Analysis ​

Sputum analysis is a critical laboratory technique employed in the diagnosis and monitoring of various respiratory diseases, particularly those involving airway inflammation, such as asthma, chronic obstructive pulmonary disease (COPD), and lung infections. This technique involves the collection and examination of sputum, which can be induced through methods like hypertonic saline inhalation, to evaluate cellular and molecular markers indicative of underlying respiratory conditions.

Sputum induction is a non-invasive and cost-effective method that allows for the analysis of inflammatory cells and biomarkers in the airways. The primary goal of sputum analysis is to obtain a differential cell count and assess the presence of inflammatory biomarkers, including eosinophil cationic protein, eosinophil-derived neurotoxin, major basic protein, tryptase, and cytokines such as interleukin (IL)-5. These biomarkers provide insight into the pathophysiology of inflammatory respiratory disorders and can aid in diagnosing conditions like asthma, COPD, lung cancer, and infections such as tuberculosis and Pneumocystis jirovecii pneumonia [29].

The process of sputum analysis typically involves collecting samples after induction, followed by cytospin preparation for immunocytochemical staining of cellular products. This approach can enhance the understanding of the immune response and the pathophysiological processes associated with respiratory diseases. Advanced techniques, such as flow cytometry and in situ hybridization, can be applied to the sputum supernatant to further investigate the immune response [29].

In clinical practice, sputum analysis serves as a reliable diagnostic tool for lower respiratory tract infections. Properly screened expectorated sputum samples can identify pathogens in cases of bacterial pneumonia, with the technique yielding high diagnostic accuracy when correlated with initial microscopic screening and clinical presentation [30]. The presence of fewer than 25 squamous epithelial cells per low-power field in the sputum sample indicates that true lower respiratory tract secretions have been collected, enhancing the reliability of the results [30].

Moreover, the analysis of sputum can provide comparable data to more invasive procedures like bronchoalveolar lavage and bronchial biopsy. Studies have shown that induced sputum analysis can effectively assess airway inflammation, with results similar to those obtained from these more invasive techniques [31]. The technique has been increasingly recognized for its role in tailoring asthma interventions based on sputum eosinophil counts, which has been shown to reduce the frequency of asthma exacerbations compared to traditional symptom-based approaches [32].

In conclusion, sputum analysis is a valuable diagnostic tool in the evaluation of respiratory diseases, allowing for the assessment of airway inflammation and the identification of specific biomarkers that can inform treatment strategies. The technique's non-invasive nature and the breadth of information it provides make it an essential component of respiratory disease diagnosis and management.

5.3 Bronchoscopy and Biopsy ​

The diagnosis of respiratory diseases often involves various methods, with bronchoscopy and biopsy being central to the process. Bronchoscopy has been a crucial technique for over 150 years, primarily used for airway inspection, diagnosis of airway lesions, and therapeutic interventions such as aspiration of airway secretions and transbronchial biopsy for parenchymal lung disorders. Its application extends to the diagnosis of peripheral pulmonary nodules and other therapeutic treatments, although challenges remain in navigating to the lung periphery and avoiding vascular structures during biopsies (Criner et al., 2020).

Bronchoscopy techniques have evolved significantly in the last decade, facilitated by advancements in thoracic imaging and navigational platforms that aid bronchoscopists in locating lung lesions. New bronchoscopic therapies are being investigated not only for diagnosis but also for treatment of various lung diseases, including asthma, emphysema, and chronic bronchitis. These developments have broadened the diagnostic and therapeutic arsenal available to clinicians dealing with lung diseases (Criner et al., 2020).

Diagnostic techniques commonly employed during bronchoscopy include forceps biopsy, aspiration, brush cytology sampling, and needle aspiration, particularly for lung cancer. The established diagnostic techniques provide critical information regarding the extent of lung cancer, while newer technologies such as endobronchial ultrasound and electromagnetic navigation enhance the precision of these procedures (Herth et al., 2006). Furthermore, bronchoalveolar lavage (BAL) is noted for its ability to combine cytological examination with quantitative culture, making it one of the most accurate invasive diagnostic methods for pulmonary infections, especially in mechanically ventilated patients (Torres, 1991).

In addition to bronchoscopy, laboratory analyses of exhaled breath condensate (EBC) are emerging as a non-invasive diagnostic tool for respiratory diseases. EBC contains a mixture of biomarkers that can provide significant insights into inflammatory and neoplastic states within the lungs, thereby aiding in the diagnosis and monitoring of conditions such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer. The composition of EBC includes volatile and non-volatile biomarkers like cytokines and oxidative stress markers, which are indicative of physiological and pathological processes (Kita et al., 2024).

Overall, the diagnosis of respiratory diseases involves a combination of invasive techniques such as bronchoscopy and biopsy, as well as non-invasive approaches like the analysis of EBC. These methods allow for a comprehensive assessment of lung conditions, enabling effective management and treatment strategies tailored to individual patient needs.

6 Challenges and Limitations in Diagnosis ​

6.1 Misdiagnosis and Overlapping Symptoms ​

Respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and other conditions, present significant challenges in diagnosis due to their complex nature and the overlap of symptoms with other diseases. The diagnostic process often involves clinical judgment, physiological measurements, and various diagnostic tools, yet it is fraught with potential for misdiagnosis, which can be categorized into over-diagnosis and under-diagnosis.

Misdiagnosis is a prevalent issue, with both over-diagnosis and under-diagnosis contributing to unnecessary morbidity and mortality. Over-diagnosis can lead to patients receiving treatments that expose them to unnecessary side effects, while under-diagnosis can result in avoidable health complications. For instance, in a qualitative study conducted by Akindele et al. (2019), healthcare professionals reported that clinical judgment was crucial in assessing the probability of asthma, but challenges included time constraints, the variable nature of asthma, and overlapping clinical features with conditions like respiratory viral illnesses and COPD [33].

The use of spirometry and other physiological measurements is standard in diagnosing respiratory diseases. However, the interpretation of these tests can vary significantly, leading to diagnostic inaccuracies. For example, Thomas et al. (2019) highlighted that in COPD literature, the terms "overdiagnosis" and "misdiagnosis" are often used interchangeably, frequently referring to false positive diagnoses that arise from normal spirometry results being misinterpreted as indicative of COPD [34]. Moreover, the challenges of distinguishing COPD from other comorbidities further complicate the diagnostic landscape [34].

The overlap of respiratory diseases, such as asthma and obstructive sleep apnea (OSA), introduces additional complexity. Owens et al. (2017) noted that many patients may experience both lower airway obstruction and upper airway obstruction during sleep, creating an overlap syndrome that poses unique diagnostic and therapeutic challenges [35]. This necessitates a vigilant approach from healthcare providers to accurately identify and treat these conditions, as misdiagnosis can lead to ineffective treatment and further complications.

Emerging diagnostic technologies aim to enhance the accuracy of respiratory disease diagnoses. For instance, the integration of artificial intelligence (AI) and deep learning techniques is being explored to improve diagnostic precision through advanced data analytics and imaging techniques. Pan et al. (2024) described a two-stage approach using deep learning algorithms to refine the accuracy of early-stage diagnosis of respiratory infections, demonstrating the potential of AI in navigating the complexities of medical imaging and improving healthcare outcomes [36].

Despite advancements, the diagnostic process for respiratory diseases remains challenging due to the interplay of overlapping symptoms, the limitations of current diagnostic tools, and the need for precision medicine. Continuous efforts to enhance diagnostic methodologies, including the development of better educational resources for healthcare providers and the introduction of innovative diagnostic technologies, are essential for improving the accuracy and efficacy of respiratory disease diagnoses [[pmid:31036773],[pmid:40806268]].

6.2 Accessibility and Resource Limitations ​

The diagnosis of respiratory diseases presents numerous challenges and limitations, particularly in the context of accessibility and resource constraints. Respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and various infections, are prevalent globally and pose significant health risks. However, effective diagnosis often hinges on the availability of appropriate diagnostic tools and healthcare infrastructure.

One of the primary challenges in diagnosing respiratory diseases is the lack of access to advanced diagnostic technologies, especially in resource-limited settings. Many of these regions face significant economic constraints that hinder the implementation of sophisticated diagnostic tools. For instance, while polymerase chain reaction (PCR) and other molecular diagnostic methods have revolutionized the detection of respiratory pathogens, their deployment in low-resource environments is often limited due to high costs and the need for specialized training [37].

Moreover, the accessibility of routine physiological measurements, such as spirometry, is often restricted. In many cases, healthcare systems may lack the necessary equipment or trained personnel to conduct these tests effectively [38]. This is particularly evident in low-income countries where the prevalence of respiratory diseases is high, yet the diagnostic capabilities are insufficient. Studies have shown that the under-diagnosis of asthma in children, for example, can be attributed to a combination of community knowledge deficits, healthcare accessibility issues, and the absence of essential diagnostic tests [38].

In addition to the economic and infrastructural barriers, there are also significant technical challenges associated with point-of-care diagnostics. While there has been substantial progress in developing simple and inexpensive diagnostic tools suitable for non-laboratory settings, many of these technologies still face hurdles related to sensitivity, specificity, and the overall reliability of results [37]. The effectiveness of these tools is often compromised by the variability in environmental conditions and the level of operator training required.

The complexity of respiratory diseases themselves further complicates the diagnostic process. Respiratory infections can be caused by a multitude of pathogens, and symptoms often overlap among different diseases, making accurate diagnosis challenging [3]. For instance, cough sounds can be indicative of various conditions, and while artificial intelligence (AI) has shown promise in analyzing these sounds for diagnosis, the technology is still in the early stages of implementation [39].

Finally, emerging diagnostic techniques, such as advanced imaging methods and biosensors for detecting biomarkers in exhaled breath and saliva, offer potential solutions but also face limitations regarding widespread adoption and clinical validation [2]; [21]. The integration of these novel technologies into existing healthcare frameworks is essential to enhance diagnostic capabilities and address the existing gaps in respiratory disease management.

In conclusion, while there are advancements in the diagnosis of respiratory diseases, significant challenges remain, particularly related to accessibility and resource limitations. Addressing these issues is crucial for improving diagnostic accuracy and ensuring that effective treatments can be administered in a timely manner, especially in vulnerable populations.

7 Future Directions in Diagnostic Approaches ​

7.1 Advances in Biomarkers ​

The diagnosis of respiratory diseases has significantly evolved with the advent of innovative technologies and methodologies aimed at enhancing the accuracy and efficiency of disease identification. Recent literature emphasizes the critical role of biomarkers in diagnosing respiratory conditions, highlighting several promising approaches that utilize various biological samples, including exhaled breath and saliva.

One of the foremost advancements in respiratory disease diagnostics is the utilization of audio analysis and artificial intelligence (AI). A systematic review by Kapetanidis et al. (2024) discusses how digital biomarkers derived from audio signals of the respiratory system, such as cough sounds and voice abnormalities, are being employed to identify and diagnose respiratory diseases. Machine learning algorithms have shown promise in extracting meaningful information from these audio-based biomarkers, facilitating the recognition of cough amidst background noise and the analysis of respiratory sounds for symptoms like wheezes and crackles[40].

Furthermore, biosensors have emerged as a non-invasive and efficient diagnostic tool for detecting biomarkers from exhaled breath and saliva. Xiong et al. (2025) provide a comprehensive overview of various biosensors designed to identify respiratory disease-related biomarkers, emphasizing their potential in rapid diagnostics. These biosensors include electrochemical, optical, and piezoelectric types, which are increasingly recognized for their cost-effectiveness and diagnostic capabilities[2].

The assessment of exhaled breath condensate (EBC) is another promising non-invasive method highlighted by Kita et al. (2024). EBC contains a range of volatile and non-volatile biomarkers, including cytokines and oxidative stress markers, which can provide significant insights into inflammatory and neoplastic states in the lungs. This method addresses the limitations of traditional screening techniques and is being researched for its potential in monitoring chronic diseases like asthma and chronic obstructive pulmonary disease (COPD) as well as lung cancer[8].

Machine learning techniques are also being applied to identify theranostic biomarkers that predict treatment responses in respiratory diseases. Nikolaou et al. (2022) conducted a study using a large sample size to identify biomarkers associated with treatment responses, revealing that certain biochemical markers could guide therapeutic management in respiratory conditions[41].

In addition to these methods, the exploration of breath metabolites for diagnosing infections has gained traction, particularly in light of the COVID-19 pandemic. Berna and Odom John (2021) reviewed the potential of volatile organic compounds in exhaled breath as indicators of various infectious diseases, suggesting that breath analysis could be a convenient and non-invasive diagnostic strategy[42].

Overall, the future directions in diagnostic approaches for respiratory diseases are increasingly centered around the development and application of biomarkers. These advancements not only enhance the diagnostic accuracy but also pave the way for personalized medicine, where treatment can be tailored based on individual biomarker profiles. Continuous research into novel biomarkers and the integration of AI and biosensing technologies will likely shape the future landscape of respiratory disease diagnostics, making them more accessible and efficient.

7.2 Role of Artificial Intelligence and Machine Learning ​

The diagnosis of respiratory diseases has evolved significantly with the integration of artificial intelligence (AI) and machine learning (ML) technologies. Traditional diagnostic methods often face challenges such as overlapping clinical symptoms, leading to misdiagnosis or delayed treatment. AI and ML offer innovative solutions that enhance the accuracy and efficiency of diagnosing respiratory conditions.

AI excels in analyzing large datasets and can assist in various aspects of respiratory disease diagnosis. For instance, AI algorithms have been developed to evaluate lung cancer images, diagnose fibrotic lung disease, and interpret pulmonary function tests. The use of AI in respiratory medicine is particularly promising due to its ability to work with heterogeneous data, where diagnostic criteria may overlap, such as in asthma and chronic obstructive pulmonary disease (COPD) [43]. Furthermore, AI can provide decision support to clinicians, potentially improving patient outcomes through timely and precise diagnosis [44].

Recent advancements in deep learning and vision transformer techniques have led to the development of novel datasets and diagnostic methodologies. For example, a study introduced a diverse dataset of 7,867 X-ray images covering 49 distinct pulmonary diseases, which aims to enhance the training of deep learning models and improve their generalization in clinical settings [45]. Such comprehensive datasets are crucial for developing robust AI systems capable of making accurate predictions across a range of respiratory diseases.

AI's role in respiratory disease diagnosis is further exemplified by systems like LungDiag, which utilizes natural language processing (NLP) to extract clinical features from electronic health records (EHRs). This system demonstrated superior diagnostic performance, achieving an F1 score of 0.711 for the top diagnosis and 0.927 for the top three diagnoses in a multicenter study involving over 31,000 EHRs [46]. The integration of AI in EHR analysis showcases its potential to support physicians in making more informed diagnostic decisions.

Moreover, AI-enabled microfluidic platforms have emerged as a transformative approach for detecting respiratory pathogens, providing rapid, sensitive, and cost-effective diagnostic solutions. These platforms leverage AI to optimize chip design and enhance signal interpretation, thus facilitating real-time diagnostics suitable for point-of-care applications [47].

Despite these advancements, challenges remain in the clinical implementation of AI technologies for respiratory disease diagnosis. Issues such as dataset bias, variations in data quality, and the need for extensive validation of AI models are critical areas that require attention [45]. Additionally, the successful integration of AI into clinical practice will depend on collaboration among clinicians, data scientists, and regulatory bodies to ensure the safety and efficacy of AI applications [48].

In conclusion, the future directions in diagnostic approaches for respiratory diseases will likely see an increased reliance on AI and ML technologies. These innovations promise to enhance diagnostic accuracy, streamline clinical workflows, and ultimately improve patient outcomes. Continued research and development, along with rigorous validation of AI systems, will be essential in realizing the full potential of these technologies in respiratory medicine.

8 Conclusion ​

The diagnosis of respiratory diseases has become increasingly complex, necessitating a multifaceted approach that incorporates clinical evaluation, advanced imaging techniques, pulmonary function tests, and laboratory analyses. Key findings from this review highlight the importance of thorough patient history and symptom assessment, which remain foundational to accurate diagnosis. Imaging modalities, particularly chest X-rays and CT scans, play a crucial role in visualizing lung pathology, while pulmonary function tests, such as spirometry and diffusion capacity testing, provide essential insights into lung function and disease severity. However, challenges persist, including misdiagnosis due to symptom overlap and limitations in access to diagnostic resources, particularly in low-resource settings. Future research directions emphasize the need for innovative diagnostic approaches, including the integration of biomarkers and the application of artificial intelligence and machine learning technologies, which have the potential to enhance diagnostic accuracy and personalize treatment strategies. Continued advancements in these areas are critical for improving outcomes for patients with respiratory diseases and addressing the significant global health burden they represent.

References ​

  • [1] Damla Gürkan Kuntalp;Nermin Özcan;Okan Düzyel;Fevzi Yasin Kababulut;Mehmet Kuntalp. A Comparative Study of Metaheuristic Feature Selection Algorithms for Respiratory Disease Classification.. Diagnostics (Basel, Switzerland)(IF=3.3). 2024. PMID:39410648. DOI: 10.3390/diagnostics14192244.
  • [2] Hangming Xiong;Xiaojing Zhang;Jiaying Sun;Yingying Xue;Weijie Yu;Shimeng Mou;K Jimmy Hsia;Hao Wan;Ping Wang. Recent advances in biosensors detecting biomarkers from exhaled breath and saliva for respiratory disease diagnosis.. Biosensors & bioelectronics(IF=10.5). 2025. PMID:39374569. DOI: 10.1016/j.bios.2024.116820.
  • [3] Michael Loeffelholz;Tasnee Chonmaitree. Advances in diagnosis of respiratory virus infections.. International journal of microbiology(IF=3.2). 2010. PMID:20981303. DOI: 10.1155/2010/126049.
  • [4] Abdullah;Zulaikha Fatima;Jawad Abdullah;José Luis Oropeza Rodríguez;Grigori Sidorov. A Multimodal AI Framework for Automated Multiclass Lung Disease Diagnosis from Respiratory Sounds with Simulated Biomarker Fusion and Personalized Medication Recommendation.. International journal of molecular sciences(IF=4.9). 2025. PMID:40806268. DOI: 10.3390/ijms26157135.
  • [5] Shubhagata Das;Sherry Dunbar;Yi-Wei Tang. Laboratory Diagnosis of Respiratory Tract Infections in Children - the State of the Art.. Frontiers in microbiology(IF=4.5). 2018. PMID:30405553. DOI: 10.3389/fmicb.2018.02478.
  • [6] Christine C Ginocchio. Detection of respiratory viruses using non-molecular based methods.. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology(IF=3.4). 2007. PMID:18162248. DOI: 10.1016/S1386-6532(07)70004-5.
  • [7] Michael J Falvo;Anays M Sotolongo;John J Osterholzer;Michelle W Robertson;Ella A Kazerooni;Judith K Amorosa;Eric Garshick;Kirk D Jones;Jeffrey R Galvin;Kathleen Kreiss;Stella E Hines;Teri J Franks;Robert F Miller;Cecile S Rose;Mehrdad Arjomandi;Silpa D Krefft;Michael J Morris;Vasiliy V Polosukhin;Paul D Blanc;Jeanine M D'Armiento. Consensus Statements on Deployment-Related Respiratory Disease, Inclusive of Constrictive Bronchiolitis: A Modified Delphi Study.. Chest(IF=8.6). 2023. PMID:36343686. DOI: 10.1016/j.chest.2022.10.031.
  • [8] Karolina Kita;Marika Gawinowska;Marta Chełmińska;Marek Niedoszytko. The Role of Exhaled Breath Condensate in Chronic Inflammatory and Neoplastic Diseases of the Respiratory Tract.. International journal of molecular sciences(IF=4.9). 2024. PMID:39000502. DOI: 10.3390/ijms25137395.
  • [9] Yaping Xie;Zisheng Zong;Qin Jiang;Xingxing Ke;Zhigang Wu. Seeking Solutions for Inclusively Economic, Rapid, and Safe Molecular Detection of Respiratory Infectious Diseases: Comprehensive Review from Polymerase Chain Reaction Techniques to Amplification-Free Biosensing.. Micromachines(IF=3.0). 2025. PMID:40283347. DOI: 10.3390/mi16040472.
  • [10] Mark O Wielpütz;Claus P Heußel;Felix J F Herth;Hans-Ulrich Kauczor. Radiological diagnosis in lung disease: factoring treatment options into the choice of diagnostic modality.. Deutsches Arzteblatt international(IF=7.1). 2014. PMID:24698073. DOI: .
  • [11] Khaled Almezhghwi;Sertan Serte;Fadi Al-Turjman. Convolutional neural networks for the classification of chest X-rays in the IoT era.. Multimedia tools and applications(IF=3.0). 2021. PMID:34155434. DOI: 10.1007/s11042-021-10907-y.
  • [12] Chunli Qin;Demin Yao;Yonghong Shi;Zhijian Song. Computer-aided detection in chest radiography based on artificial intelligence: a survey.. Biomedical engineering online(IF=3.2). 2018. PMID:30134902. DOI: 10.1186/s12938-018-0544-y.
  • [13] N L Müller. Advances in imaging.. The European respiratory journal(IF=21.0). 2001. PMID:11757638. DOI: 10.1183/09031936.01.00266901.
  • [14] Kristoffer Ostridge;Tom M A Wilkinson. Present and future utility of computed tomography scanning in the assessment and management of COPD.. The European respiratory journal(IF=21.0). 2016. PMID:27230448. DOI: 10.1183/13993003.00041-2016.
  • [15] Tomás Franquet. [Imaging techniques in the examination of the distal airways: asthma and COPD].. Archivos de bronconeumologia(IF=9.2). 2011. PMID:21640281. DOI: 10.1016/S0300-2896(11)70017-5.
  • [16] J H Wheeler;E K Fishman. Computed tomography in the management of chest infections: current status.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America(IF=7.3). 1996. PMID:8842256. DOI: 10.1093/clinids/23.2.232.
  • [17] A Pesenti;P Tagliabue;N Patroniti;R Fumagalli. Computerised tomography scan imaging in acute respiratory distress syndrome.. Intensive care medicine(IF=21.2). 2001. PMID:11398688. DOI: 10.1007/s001340100877.
  • [18] Eva M van Rikxoort;Bram van Ginneken. Automated segmentation of pulmonary structures in thoracic computed tomography scans: a review.. Physics in medicine and biology(IF=3.4). 2013. PMID:23956328. DOI: 10.1088/0031-9155/58/17/R187.
  • [19] Miranda Kirby;Harvey O Coxson;Grace Parraga. Pulmonary functional magnetic resonance imaging for paediatric lung disease.. Paediatric respiratory reviews(IF=4.0). 2013. PMID:23522599. DOI: .
  • [20] Monika Eichinger;Ralf Tetzlaff;Michael Puderbach;Neil Woodhouse;H-U Kauczor. Proton magnetic resonance imaging for assessment of lung function and respiratory dynamics.. European journal of radiology(IF=3.3). 2007. PMID:17889475. DOI: 10.1016/j.ejrad.2007.08.007.
  • [21] Chuan T Foo;David Langton;Bruce R Thompson;Francis Thien. Functional lung imaging using novel and emerging MRI techniques.. Frontiers in medicine(IF=3.0). 2023. PMID:37181360. DOI: 10.3389/fmed.2023.1060940.
  • [22] Laura L Walkup;Nara S Higano;Jason C Woods. Structural and Functional Pulmonary Magnetic Resonance Imaging in Pediatrics-From the Neonate to the Young Adult.. Academic radiology(IF=3.9). 2019. PMID:30228041. DOI: 10.1016/j.acra.2018.08.006.
  • [23] H U Kauczor;X J Chen;E J van Beek;W G Schreiber. Pulmonary ventilation imaged by magnetic resonance: at the doorstep of clinical application.. The European respiratory journal(IF=21.0). 2001. PMID:11488304. DOI: 10.1183/09031936.01.17510080.
  • [24] V Lopez-Majano;G Renzi. Indications for pulmonary function testing.. Respiration; international review of thoracic diseases(IF=3.8). 1978. PMID:622518. DOI: 10.1159/000193859.
  • [25] Bin-Miao Liang;David C L Lam;Yu-Lin Feng. Clinical applications of lung function tests: a revisit.. Respirology (Carlton, Vic.)(IF=6.3). 2012. PMID:22329710. DOI: 10.1111/j.1440-1843.2012.02149.x.
  • [26] Hye Jeon Hwang;Eric A Hoffman;Chang Hyun Lee;Jin Mo Goo;David L Levin;Hans-Ulrich Kauczor;Joon Beom Seo. The role of dual-energy computed tomography in the assessment of pulmonary function.. European journal of radiology(IF=3.3). 2017. PMID:27865580. DOI: 10.1016/j.ejrad.2016.11.010.
  • [27] Haythem Rehouma;Rita Noumeir;Sandrine Essouri;Philippe Jouvet. Advancements in Methods and Camera-Based Sensors for the Quantification of Respiration.. Sensors (Basel, Switzerland)(IF=3.5). 2020. PMID:33348827. DOI: 10.3390/s20247252.
  • [28] M G Balzanelli;P Distratis;R Lazzaro;V H Pham;R Del Prete;G Dipalma;F Inchingolo;S K Aityan;L T Hoang;A Palermo;K C D Nguyen;C Gargiulo Isacco. The importance of arterial blood gas analysis as a systemic diagnosis approach in assessing and preventing chronic diseases, from emergency medicine to the daily practice.. European review for medical and pharmacological sciences(IF=3.3). 2023. PMID:38095412. DOI: 10.26355/eurrev_202312_34603.
  • [29] Beatriz Goncalves;Ukpai A Eze. Sputum induction and its diagnostic applications in inflammatory airway disorders: a review.. Frontiers in allergy(IF=3.1). 2023. PMID:37901763. DOI: 10.3389/falgy.2023.1282782.
  • [30] S M Joyce. Sputum analysis and culture.. Annals of emergency medicine(IF=5.0). 1986. PMID:3946881. DOI: 10.1016/s0196-0644(86)80576-5.
  • [31] Chang Keun Kim;John B Hagan. Sputum tests in the diagnosis and monitoring of asthma.. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology(IF=4.7). 2004. PMID:15328669. DOI: 10.1016/S1081-1206(10)61462-7.
  • [32] Helen L Petsky;Albert Li;Anne B Chang. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults.. The Cochrane database of systematic reviews(IF=9.4). 2017. PMID:28837221. DOI: 10.1002/14651858.CD005603.pub3.
  • [33] Adeola Akindele;Luke Daines;Debbie Cavers;Hilary Pinnock;Aziz Sheikh. Qualitative study of practices and challenges when making a diagnosis of asthma in primary care.. NPJ primary care respiratory medicine(IF=4.7). 2019. PMID:31316068. DOI: 10.1038/s41533-019-0140-z.
  • [34] Elizabeth T Thomas;Paul Glasziou;Claudia C Dobler. Use of the terms "overdiagnosis" and "misdiagnosis" in the COPD literature: a rapid review.. Breathe (Sheffield, England)(IF=3.4). 2019. PMID:31031840. DOI: 10.1183/20734735.0354-2018.
  • [35] Robert L Owens;Madalina M Macrea;Mihaela Teodorescu. The overlaps of asthma or COPD with OSA: A focused review.. Respirology (Carlton, Vic.)(IF=6.3). 2017. PMID:28677827. DOI: 10.1111/resp.13107.
  • [36] Cheng-Tang Pan;Rahul Kumar;Zhi-Hong Wen;Chih-Hsuan Wang;Chun-Yung Chang;Yow-Ling Shiue. Improving Respiratory Infection Diagnosis with Deep Learning and Combinatorial Fusion: A Two-Stage Approach Using Chest X-ray Imaging.. Diagnostics (Basel, Switzerland)(IF=3.3). 2024. PMID:38472972. DOI: 10.3390/diagnostics14050500.
  • [37] ShuQi Wang;Mark A Lifson;Fatih Inci;Li-Guo Liang;Ye-Feng Sheng;Utkan Demirci. Advances in addressing technical challenges of point-of-care diagnostics in resource-limited settings.. Expert review of molecular diagnostics(IF=3.6). 2016. PMID:26777725. DOI: 10.1586/14737159.2016.1142877.
  • [38] P Magwenzi;S Rusakaniko;E N Sibanda;F Z Gumbo. Challenges in the diagnosis of asthma in children, what are the solutions? A scoping review of 3 countries in sub Saharan Africa.. Respiratory research(IF=5.0). 2022. PMID:36123720. DOI: 10.1186/s12931-022-02170-y.
  • [39] Kawther S Alqudaihi;Nida Aslam;Irfan Ullah Khan;Abdullah M Almuhaideb;Shikah J Alsunaidi;Nehad M Abdel Rahman Ibrahim;Fahd A Alhaidari;Fatema S Shaikh;Yasmine M Alsenbel;Dima M Alalharith;Hajar M Alharthi;Wejdan M Alghamdi;Mohammed S Alshahrani. Cough Sound Detection and Diagnosis Using Artificial Intelligence Techniques: Challenges and Opportunities.. IEEE access : practical innovations, open solutions(IF=3.6). 2021. PMID:34786317. DOI: 10.1109/ACCESS.2021.3097559.
  • [40] Panagiotis Kapetanidis;Fotios Kalioras;Constantinos Tsakonas;Pantelis Tzamalis;George Kontogiannis;Theodora Karamanidou;Thanos G Stavropoulos;Sotiris Nikoletseas. Respiratory Diseases Diagnosis Using Audio Analysis and Artificial Intelligence: A Systematic Review.. Sensors (Basel, Switzerland)(IF=3.5). 2024. PMID:38400330. DOI: 10.3390/s24041173.
  • [41] Vasilis Nikolaou;Sebastiano Massaro;Masoud Fakhimi;Wolfgang Garn. Using Machine Learning to Detect Theranostic Biomarkers Predicting Respiratory Treatment Response.. Life (Basel, Switzerland)(IF=3.4). 2022. PMID:35743805. DOI: 10.3390/life12060775.
  • [42] Amalia Z Berna;Audrey R Odom John. Breath Metabolites to Diagnose Infection.. Clinical chemistry(IF=6.3). 2021. PMID:34969107. DOI: 10.1093/clinchem/hvab218.
  • [43] Alan Kaplan;Hui Cao;J Mark FitzGerald;Nick Iannotti;Eric Yang;Janwillem W H Kocks;Konstantinos Kostikas;David Price;Helen K Reddel;Ioanna Tsiligianni;Claus F Vogelmeier;Pascal Pfister;Paul Mastoridis. Artificial Intelligence/Machine Learning in Respiratory Medicine and Potential Role in Asthma and COPD Diagnosis.. The journal of allergy and clinical immunology. In practice(IF=6.6). 2021. PMID:33618053. DOI: 10.1016/j.jaip.2021.02.014.
  • [44] Mingyu Wang;Luhan Li;Min Feng;Zhuo Liu. Advances in artificial intelligence applications for the management of chronic obstructive pulmonary disease.. Frontiers in medicine(IF=3.0). 2025. PMID:41164160. DOI: 10.3389/fmed.2025.1685254.
  • [45] Amer Alghadhban;Rabie A Ramadan;Meshari Alazmi. Advancing respiratory disease diagnosis: A deep learning and vision transformer-based approach with a novel X-ray dataset.. Computers in biology and medicine(IF=6.3). 2025. PMID:40494170. DOI: 10.1016/j.compbiomed.2025.110501.
  • [46] Hengrui Liang;Tao Yang;Zihao Liu;Wenhua Jian;Yilong Chen;Bingliang Li;Zeping Yan;Weiqiang Xu;Luming Chen;Yifan Qi;Zhiwei Wang;Yajing Liao;Peixuan Lin;Jiameng Li;Wei Wang;Li Li;Meijia Wang;YunHui Zhang;Lizong Deng;Taijiao Jiang;Jianxing He. LungDiag: Empowering artificial intelligence for respiratory diseases diagnosis based on electronic health records, a multicenter study.. MedComm(IF=10.7). 2025. PMID:39802635. DOI: 10.1002/mco2.70043.
  • [47] Daoguangyao Zhang;Xuefei Lv;Hao Jiang;Yunlong Fan;Kexin Liu;Hao Wang;Yulin Deng. AI-Enabled Microfluidics for Respiratory Pathogen Detection.. Sensors (Basel, Switzerland)(IF=3.5). 2025. PMID:41013029. DOI: 10.3390/s25185791.
  • [48] Alex K Pearce;Shamim Nemati;Ewan C Goligher;Catherine L Hough;Andre L Holder;Gabriel Wardi;Philip Yang;Aaron Boussina;Patrick G Lyons;Sarina Sahetya;Atul Malhotra;Angela Rogers. Can we predict the future of respiratory failure prediction?. Critical care (London, England)(IF=9.3). 2025. PMID:40537867. DOI: 10.1186/s13054-025-05484-7.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Respiratory Diseases · Diagnostic Approaches · Medical Technology · Artificial Intelligence · Biomarkers

© 2025 MaltSci